Background
==========

Diabetes and diabetic nephropathy (DN), a major and specific microvascular complication of diabetes, are increasingly prevalent and have become serious health problems. DN exhibits a high incidence rate in patients with diabetes and remains the main cause of end-stage renal disease \[[@b1-medscimonit-23-428]\].

Although the mechanisms by which diabetic patients develop DN are not completely understood, hyperglycemic exposure, hypertension, and other factors such as high levels of advanced glycation end products, oxidative stress, inflammation, and protein kinase C are generally considered to be risk factors for DN. The Steno-2 study showed that strict metabolic control can effectively inhibit the progression of DN \[[@b2-medscimonit-23-428]\]. However, some individuals suffer from DN despite rigid metabolic control. The limited efficacy of current interventions, familial aggregation of DN, and clustering of DN within ethnic groups indicate that a genetic factor may contribute to susceptibility to DN \[[@b3-medscimonit-23-428]\].

Pentraxin 3 (*PTX3*), a form of long pentraxin, is a member of the acute-phase reactants superfamily and shares structural homology with short pentraxins, such as C-reactive protein (CRP) and serum amyloid P component \[[@b4-medscimonit-23-428]\]. *PTX3* is produced by several cell types, most prominently by endothelial cells and monocytes, in response to inflammation. *PTX3* is a sensitive biomarker of localized inflammatory reactions \[[@b4-medscimonit-23-428],[@b5-medscimonit-23-428]\] and is associated with a variety of clinical diseases, including coronary artery disease, rheumatoid arthritis, sepsis \[[@b5-medscimonit-23-428]\], and chronic kidney diseases (CKD) \[[@b6-medscimonit-23-428],[@b7-medscimonit-23-428]\]. Previous studies have suggested that DN is a low-grade chronic inflammatory disease \[[@b8-medscimonit-23-428],[@b9-medscimonit-23-428]\]. Altered plasma levels of *PTX3* are associated with development of DN \[[@b6-medscimonit-23-428],[@b10-medscimonit-23-428],[@b11-medscimonit-23-428]\]; plasma *PTX3* levels are inversely associated with eGFR, but positively associated with levels of albuminuria/proteinuria in patients with DN. Hence, *PTX3* may be implicated in the development of DN.

Single nucleotide polymorphisms (SNPs) in *PTX3* have been found to influence circulating *PTX3* levels \[[@b10-medscimonit-23-428],[@b12-medscimonit-23-428]--[@b15-medscimonit-23-428]\] and are associated with the risk of some diseases, including primary graft dysfunction after lung transplantation \[[@b13-medscimonit-23-428]\], pulmonary tuberculosis \[[@b16-medscimonit-23-428]\], and development of hepatocellular carcinoma in patients with chronic hepatitis C (CHC) \[[@b15-medscimonit-23-428]\]. However, no data are available on the association between *PTX3* polymorphisms and DN in patients with diabetes. Previous studies have shown that certain regions on chromosome 3q are associated with an increased susceptibility to DN, based on genome-wide scanning and linkage analysis \[[@b17-medscimonit-23-428],[@b18-medscimonit-23-428]\]. *PTX3* is located on chromosome 3 at band q25. We hypothesized that variants of *PTX3* may be associated with an increased risk of developing DN. The primary goal of the present study was to assess the relationship between *PTX3* variants and DN in Han Chinese patients with type 2 diabetes.

Material and Methods
====================

Participants
------------

A total of 442 participants were recruited from the First Affiliated Hospital of Wenzhou Medical University between December 2015 and June 2016 for this case-control study. They included 290 patients known to have type 2 diabetes for longer than five years and 152 gender-matched normal controls (NC). All participants were unrelated and of Han Chinese ethnicity. Eligible patients with type 2 diabetes were categorized into two groups: the non-diabetic nephropathy (NDN) group (n=155) and the diabetic nephropathy (DN) group (n=135). Patients with type 2 diabetes were diagnosed according to the diagnostic criteria of the American Diabetes Association (ADA) published in 2016 \[[@b19-medscimonit-23-428]\]. Albuminuria was determined according to the urine albumin-to-creatinine ratio (ACR) suggested by the ADA \[[@b19-medscimonit-23-428]\]. Estimation of the glomerular filtration rate (eGFR) was performed using the Chronic Kidney Disease Epidemiology Collaboration formula. DN was defined on the basis of persistent microalbuminuria detected during at least two examinations (ACR \>30 mg/g) or overt albuminuria (ACR \>300 mg/g), with or without eGFR \<60 mL/min/1.73 m^2^ and in the presence of diabetic retinopathy. Patients with another kidney diseases, inflammatory diseases, pregnancy, or congestive heart disease were excluded from the study. Patients with ACR \<30 mg/g and eGFR \>60 mL/min/1.73 m^2^ were considered NDN.

All procedures were performed in accordance with the Declaration of Helsinki and informed consent was obtained from each individual. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University.

Genotyping
----------

Samples of whole blood were collected from each participant. Genomic DNA was extracted using a DNA Purification Kit (TIANNamp Blood DNA Kit; Tiangen Biotech, China), according to the manufacturer's instructions. Individual DNA samples were genotyped using the ABI PRISM SNapshot method (Applied Biosystems, CA, USA). Eight SNPs (rs2305619, rs2120243, rs1456099, rs7634847, rs1840680, rs2316706, rs2316709, and rs7616177) in *PTX3* were analyzed. The SNapshot reactions were performed in a total reaction volume of 8 μL containing SNapshot Multiplex reagent (5 μL), extended primer mix (1 μL), and templates (2 μL), which consisted of purified multiplex polymerase chain reaction (PCR) products. The extension products were purified by incubation with 1 unit of shrimp alkaline phosphatase (SAP) at 37°C for 60 minutes and a subsequent incubation at 85°C for 15 minutes for enzyme inactivation. The purified products (1 μL), GeneScan-120 LIZ Size Standard (Applied Biosystems, 0.5 μL), and HI-DI (8.5 μL) were mixed and identified using an ABI 3730 sequencer (Applied Biosystems). Finally, the results were analyzed with GeneMapper 4.0 software (Applied Biosystems Co., Ltd., USA).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). Continuous variables with normal distribution are shown as mean ± standard deviation (SD). Differences between groups were analyzed using by Student's *t*-test and differences among groups were tested by one-way analysis of variance (ANOVA). Categorical data were examined using the chi-square test. The chi-square test was also used to evaluate whether genotype and allele frequencies were in Hardy-Weinberg equilibrium (HWE). The association of each SNP with the risk for DN was analyzed by multivariate logistic regression using the stepwise backward approach; odds ratios (OR), and 95% confidence intervals (95% CI) were also calculated. Estimates of linkage disequilibrium between SNPs were determined by calculating pairwise *D'* and *r^2^* statistics using Haploview (version 4.2; *[www.broad.mit.edu/mpg/haploview/](www.broad.mit.edu/mpg/haploview/)*); haplotype analysis was also performed using this software. Differences were considered statistically significant when *p*\<0.05.

Results
=======

Baseline characteristics
------------------------

The baseline characteristics of the study participants in the DN, NDN, and NC groups are shown in [Table 1](#t1-medscimonit-23-428){ref-type="table"}. The groups showed no significant differences in gender ratio (*p*\>0.05). Patients in the DN group were older than those in the NDN and NC groups (*p*\<0.05). The proportion of patients with hypertension was significantly higher in the DN group than in the NDN and NC groups (*p*\<0.01). Compared with the NDN group, patients in the DN group had a longer duration of diabetes (*p*=0.041). The levels of fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1C) in patients with diabetes were significantly higher than those of patients in the NC group (all *p*\<0.01). eGFR was lower in the DN group than in the NC group (*p*\<0.01).

Associations between PTX3 SNPs and DN in patients with T2DM
-----------------------------------------------------------

As shown in [Table 2](#t2-medscimonit-23-428){ref-type="table"}, the genotype frequencies of rs2305619 differed significantly between the DN and the NDN groups (*p*\<0.05), and the allele frequencies of rs2305619 differed significantly between the DN and the NDN groups (*p*\<0.05). Patients with the GG variant showed 4.078-fold higher susceptibility to DN than those with the AA variant (OR=4.078, 95% CI=1.370--12.135, *p*=0.012, [Table 3](#t3-medscimonit-23-428){ref-type="table"}). The genotype frequencies of rs2120243 differed significantly between the DN and the NDN groups (*p*\<0.05, [Table 2](#t2-medscimonit-23-428){ref-type="table"}). We detected a lower risk of developing DN in individuals with the AA variant of rs2120243 (OR=0.213, 95% CI=0.055--0.826, *p*=0.025, [Table 3](#t3-medscimonit-23-428){ref-type="table"}). In addition, the A allele appeared to decrease the susceptibility to DN (OR=0.688, 95% CI=0.476--0.994, *p*=0.046, [Table 3](#t3-medscimonit-23-428){ref-type="table"}), which suggested that the A allele of rs2120243 may be a protective factor against DN in diabetic patients. Although the genotype and allele frequencies of rs1840680 did not differ significantly between the DN and NDN groups (*p*\>0.05, [Table 2](#t2-medscimonit-23-428){ref-type="table"}), we found that AA homozygous individuals showed a lower risk of DN than GG homozygous individuals (OR=0.370, 95% CI=0.140--0.977, *p*=0.045, [Table 3](#t3-medscimonit-23-428){ref-type="table"}). Similarly, for rs2316706, no differences in genotype or allele frequency were observed between the DN and NDN groups (*p*\>0.05, [Table 2](#t2-medscimonit-23-428){ref-type="table"}); however, the TT genotype exhibited a protective effect against DN (OR=0.345, 95% CI=0.132--0.903, *p*=0.030, [Table 3](#t3-medscimonit-23-428){ref-type="table"}). With respect to rs1456099, rs7634847, rs2316709, and rs7616177, no evidence of association with DN was found (all *p*\>0.05, [Tables 2](#t2-medscimonit-23-428){ref-type="table"}, [3](#t3-medscimonit-23-428){ref-type="table"}).

Haplotype analysis of *PTX3* SNPs
---------------------------------

We quantified the linkage disequilibrium (LD) between the two *PTX3* SNPs found to show a significant association with DN. We also investigated whether certain *PTX3* haplotypes, or combinations of alleles at different *loci*, were associated with an increased risk of DN. We identified one haplotype block in our population ([Figure 1](#f1-medscimonit-23-428){ref-type="fig"}). We compared haplotype distributions between the DN and NDN groups, and observed that the CAGGG haplotype in block 1 was associated with DN (*p*=0.0319) ([Table 4](#t4-medscimonit-23-428){ref-type="table"}).

Associations between *PTX3* and type 2 diabetes
-----------------------------------------------

As shown in [Table 5](#t5-medscimonit-23-428){ref-type="table"}, no difference in the allele frequencies of the eight SNPs was observed between the NC and T2DM groups (all *p*\>0.05).

Discussion
==========

*PTX3* is synthesized in extrahepatic tissues and cells, including atherosclerotic lesions \[[@b20-medscimonit-23-428]\], adipose tissue \[[@b21-medscimonit-23-428]\], vascular endothelial cells, and macrophages \[[@b5-medscimonit-23-428]\]. A previous study in a mouse model showed that *PTX3* is expressed in peritubular endothelial cells of the kidney \[[@b22-medscimonit-23-428]\]. In humans, expression of *PTX3* is also observed in primary proximal renal tubular epithelial cells (PTECs), primary mesangial cells, and renal fibroblasts in kidney tissues \[[@b23-medscimonit-23-428],[@b24-medscimonit-23-428]\]. Furthermore, increased plasma levels of *PTX3* were observed in patients with CKD \[[@b11-medscimonit-23-428]--[@b13-medscimonit-23-428]\] and DN \[[@b12-medscimonit-23-428],[@b14-medscimonit-23-428],[@b25-medscimonit-23-428]\]. In addition, plasma *PTX3* levels and urinary protein excretion can normalize though the treatment of the renin-angiotensin system, and/or with calcium channel blockers can normalize in patients with type 2 diabetes who show proteinuria \[[@b25-medscimonit-23-428],[@b26-medscimonit-23-428]\]. All the aforementioned evidence suggests that abnormal *PTX3* expression may contribute to renal damage.

Here, we provide evidence of the association between *PTX3* variants and DN in a population of Han Chinese patients with type 2 diabetes. We found that variants of rs2305619 and rs2120243 in *PTX3* were associated with susceptibility to DN in patients with diabetes. The SNPs rs2305619 and rs2120243 are located in the first intron and the 5′ promoter region of *PTX3*, respectively. These two SNPs may alter transcriptional regulation, resulting in abnormal splicing, or the translational dynamics of the *PTX3*, as implied in previous studies that identified an association between rs2305619 and rs2120243 and plasma *PTX3* levels \[[@b13-medscimonit-23-428]--[@b15-medscimonit-23-428]\]. It is equally possible that these two SNPs may be in linkage disequilibrium with other functional *loci* for development of DN in patients with diabetes. Further investigation is needed to clarify the role of these two SNPs in the pathogenesis of DN.

Although we identified a role of *PTX3* in the pathogenesis of DN, the mechanism remains unclear. According to studies published to date, several mechanisms might be implicated in the process of renal function impairment in T2DM, including endothelial dysfunction and/or chronic low-grade inflammation. Endothelial dysfunction is an important contributor to the development of DN \[[@b27-medscimonit-23-428],[@b28-medscimonit-23-428]\], as endothelial dysfunction influences mesangial cell and podocyte function and increases the permeability of glomerular basement membrane \[[@b27-medscimonit-23-428]\]. Indeed, *PTX3* is known to be linked to endothelial dysfunction \[[@b29-medscimonit-23-428],[@b30-medscimonit-23-428]\], and endothelial dysfunction has been reported to be ameliorated by suppression of *PTX3* expression \[[@b31-medscimonit-23-428]\]. Given the strong links among *PTX3*, endothelial dysfunction, and DN, *PTX3* may play a role in renal damage through endothelial dysfunction. In addition, inflammatory processes may be a main cause of endothelial dysfunction \[[@b32-medscimonit-23-428]\]. *PTX3* is produced at sites of inflammation and regulated by stimulation with proinflammatory stimuli (IL-1β and TNF-α) \[[@b24-medscimonit-23-428]\] and via the activation of toll-like receptors (TLRs) \[[@b22-medscimonit-23-428]\], and via several pathways, including the PI3K/Akt axis and the NF-κB pathway \[[@b5-medscimonit-23-428]\]. Moreover, these proinflammatory cytokines and signaling pathways are also known to be crucial for development of DN \[[@b33-medscimonit-23-428]\]. On the basis of these findings, we speculate that *PTX3* may act as an inflammatory mediator for the process of DN. We are interested in further investigation of the molecular mechanisms underlying the action of *PTX3* in the development of DN.

Although plasma *PTX3* level has previously been shown to be related to insulin resistance \[[@b34-medscimonit-23-428],[@b35-medscimonit-23-428]\] and insulin secretion \[[@b21-medscimonit-23-428]\], we failed to detect a significant association between *PTX3* polymorphisms and susceptibility to diabetes mellitus in this population.

Our study had several limitations. First, the sample size was relatively small, and only Chinese individuals were included, which limits the power of our results. Additionally, we did not measure plasma concentrations of *PTX3* in these individuals. Thus, further studies in a larger, ethnically diverse population are necessary to elucidate the role of *PTX3* in development of DN.

Conclusions
===========

In conclusion, the present study found that certain variants of *PTX3* predispose Han Chinese patients with type 2 diabetes to DN.
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###### 

The baseline characteristics of subjects among DN, NDN and NC group.

  Parameters                   NC (n=152)   NDN (n=155)   P[\*](#tfn2-medscimonit-23-428){ref-type="table-fn"}   DN (n=135)    P[\#](#tfn3-medscimonit-23-428){ref-type="table-fn"}   P[&](#tfn4-medscimonit-23-428){ref-type="table-fn"}
  ---------------------------- ------------ ------------- ------------------------------------------------------ ------------- ------------------------------------------------------ -----------------------------------------------------
  Male/Female                  67/85        81/74         0.152                                                  68/67         0.286                                                  0.748
  Age (years)                  59.4±11.4    59.6±10.5     0.854                                                  62.5±11.17    0.022                                                  0.027
  Course of diabetes (years)   --           11.8±4.6      --                                                     13.1±7.7      --                                                     0.041
  HbA1C                        5.66±0.36    9.51±8.51     \<0.001                                                9.12±2.09     \<0.001                                                0.579
  Hypertension                 66 (43.4%)   82 (52.9%)    0.096                                                  108 (80.0%)   \<0.001                                                \<0.001
  FPG (mmol/L)                 5.35±0.58    7.18±2.84     \<0.001                                                8.37±12.67    0.004                                                  0.290
  TC (mmol/L)                  5.18±1.05    4.70±1.24     \<0.001                                                5.07±1.64     0.475                                                  0.031
  TG (mmol/L)                  1.68±1.33    1.97±1.41     0.057                                                  2.16±1.98     0.015                                                  0.375
  HDL (mmol/L)                 1.29±0.31    1.11±0.31     \<0.001                                                1.13±0.38     \<0.001                                                0.616
  LDL (mmol/L)                 2.96±0.85    2.64±0.89     0.002                                                  2.79±1.15     0.152                                                  0.239
  eGFR (mL/min/1.73 m^2^)      98.3±14.1    100.8±18.8    0.073                                                  91.1±20.4     \<0.001                                                0.055
  LnACR (mg/g)                 --           1.89±0.76     --                                                     5.44±1.68     --                                                     \<0.001

NC -- normal control; DN -- diabetic nephropathy; NDN -- non-diabetic nephropathy; HbA~1C~ -- glycosylated hemoglobin; FPG -- fasting plasma glucose; TC -- total cholesterol; TG -- triglyceride; HDL -- high-density lipoprotein; LDL -- low-density lipoprotein; eGFR -- estimated glomerular filtration rate; LnACR -- Log~e~ transformation of albumin-to-creatinine ratio.

Comparing the NC group with the NDN group;

Comparing the NC group with the DN group;

Comparing the DN group with the NDN group.

###### 

The distributions of genotype and allele of *PTX3* SNPs in patients with diabetic nephropathy (DN group), non-diabetic nephropathy (NDN group) and normal controls (NC group) (n/%).

  Genotypes/Allele   NC (n=152)    NDN (n=155)   P[\*](#tfn6-medscimonit-23-428){ref-type="table-fn"}   DN (n=135)    P[\#](#tfn7-medscimonit-23-428){ref-type="table-fn"}   P[&](#tfn8-medscimonit-23-428){ref-type="table-fn"}   
  ------------------ ------------- ------------- ------------------------------------------------------ ------------- ------------------------------------------------------ ----------------------------------------------------- -------
  rs2305619          GG            62 (40.8%)    52 (33.5%)                                             0.339         55 (40.7%)                                             0.008                                                 0.017
  GA                 69 (45.4%)    83 (53.5%)                                                           75 (55.6%)                                                                                                                 
  AA                 21 (13.8%)    20 (13.4%)                                                           5 (3.7%)                                                                                                                   
  G                  193 (63.5%)   187 (60.3%)   0.420                                                  185 (68.5%)   0.204                                                  0.040                                                 
  rs2120243          A             111 (36.5%)   123 (39.7%)                                                          85 (31.5%)                                                                                                   
  CC                 68 (44.7%)    55 (35.5%)    0.200                                                  61 (45.2%)    0.038                                                  0.033                                                 
  CA                 70 (46.1%)    87 (56.1%)                                                           71 (52.6%)                                                                                                                 
  AA                 14 (9.2%)     13 (8.4%)                                                            3 (2.2%)                                                                                                                   
  C                  206 (66.8%)   198 (63.9%)   0.309                                                  193 (71.5%)   0.345                                                  0.051                                                 
  rs1456099          A             98 (32.2%)    112 (36.1%)                                                          77 (28.5)                                                                                                    
  TT                 40 (26.3%)    48 (31.0%)    0.493                                                  35 (25.9%)    0.907                                                  0.605                                                 
  TA                 73 (48%)      75 (48.4%)                                                           68 (50.4%)                                                                                                                 
  AA                 39 (25.7%)    32 (20.6%)                                                           32 (23.7%)                                                                                                                 
  T                  153 (50.3%)   171 (55.2%)   0.230                                                  138 (51.1%)   0.852                                                  0.329                                                 
  rs7634847          A             151 (49.7%)   139 (44.8%)                                                          132 (48.9%)                                                                                                  
  GG                 94 (61.8%)    94 (60.6%)    0.952                                                  89 (65.9%)    0.534                                                  0.370                                                 
  GA                 53 (34.9%)    55 (35.5%)                                                           44 (32.6%)                                                                                                                 
  AA                 5 (3.3%)      6 (3.9%)                                                             2 (1.5%)                                                                                                                   
  G                  241 (79.3%)   243 (78.4%)   0.787                                                  222 (82.2%)   0.372                                                  0.248                                                 
  rs1840680          A             63 (20.7%)    67 (21.6%)                                                           48 (17.8%)                                                                                                   
  GG                 67 (44.1%)    54 (34.8%)    0.189                                                  59 (43.7%)    0.134                                                  0.123                                                 
  GA                 66 (43.4%)    83 (53.5%)                                                           68 (50.4%)                                                                                                                 
  AA                 19 (12.5%)    18 (11.6%)                                                           8 (5.9%)                                                                                                                   
  G                  200 (65.8%)   191 (61.6%)   0.282                                                  186 (68.9%)   0.430                                                  0.067                                                 
  rs2316706          A             104 (34.2%)   119 (38.4%)                                                          84 (31.1%)                                                                                                   
  GG                 70 (46.1%)    58 (37.4%)    0.260                                                  60 (44.4%)    0.112                                                  0.136                                                 
  GT                 63 (41.4%)    78 (50.3%)                                                           67 (49.6%)                                                                                                                 
  TT                 19 (12.5%)    19 (12.3%)                                                           8 (9.3%)                                                                                                                   
  G                  203 (66.8%)   194 (62.6%)   0.277                                                  187 (69.3%)   0.525                                                  0.091                                                 
  rs2316709          T             101 (33.2%)   116 (37.4%)                                                          83 (30.7%)                                                                                                   
  AA                 65 (43.8%)    53 (34.2%)    0.210                                                  59 (43.7%)    0.088                                                  0.084                                                 
  AG                 73 (48.0%)    90 (58.1%)                                                           72 (53.3%)                                                                                                                 
  GG                 14 (9.2%)     12 (7.7%)                                                            4 (3.0%)                                                                                                                   
  rs7616177          A             203 (66.8%)   196 (63.2%)                                            0.356         190 (70.4%)                                            0.355                                                 0.069
  G                  101 (33.2%)   114 (36.8%)                                                          80 (29.6%)                                                                                                                 
  GG                 70 (46.1%)    57 (36.8%)    0.057                                                  61 (45.2%)    0.028                                                  0.172                                                 
  GA                 64 (42.1%)    86 (55.5%)                                                           69 (51.1%)                                                                                                                 
  AA                 18 (11.8%)    12 (7.7%)                                                            5 (3.7%)                                                                                                                   
  G                  204 (67.1%)   200 (64.5%)   0.499                                                  191 (70.7%)   0.348                                                  0.111                                                 
  A                  100 (32.9%)   110 (35.5%)                                                          79 (29.3%)                                                                                                                 

NC -- normal control; DN -- diabetic nephropathy; NDN -- non-diabetic nephropathy.

Comparing the NC group with the NDN group;

Comparing the NC group with the DN group;

Comparing the DN group with the NDN group.

###### 

Associations of *PTX3* SNPs with the risk of diabetic nephropathy in type 2 diabetic patients.

  Genotypes/Allele   OR (95%CI)              P       
  ------------------ ----------------------- ------- --
  rs2305619          AA                      Ref.    
  AG                 3.411 (1.173--9.923)    0.024   
  GG                 4.078 (1.370--12.135)   0.012   
  A                  Ref.                            
  G                  1.424 (0.993--2.041)    0.054   
  rs2120243          CC                      Ref.    
  CA                 0.706 (0.424--1.174)    0.179   
  AA                 0.213 (0.055--0.826)    0.025   
  C                  Ref.                            
  A                  0.688 (0.476--0.994)    0.046   
  rs1456099          TT                      Ref.    
  TA                 1.447 (0.813--2.575)    0.209   
  AA                 1.573 (0.786--3.147)    0.201   
  T                  Ref.                            
  A                  1.267 (0.897--1.789)    0.179   
  rs7634847          GG                      Ref.    
  GA                 0.812 (0.481--1.370)    0.436   
  AA                 0.354 (0.065--1.917)    0.228   
  G                  Ref.                            
  A                  0.765 (0.495--1.183)    0.228   
  rs1840680          GG                      Ref.    
  GA                 0.722 (0.430--1.213)    0.218   
  AA                 0.370 (0.140--0.977)    0.045   
  G                  Ref.                            
  A                  0.703 (0.489--1.010)    0.056   
  rs2316706          GG                      Ref.    
  GT                 0.815 (0.486--1.365)    0.436   
  TT                 0.345 (0.132--0.903)    0.030   
  G                  Ref.                            
  T                  0.711 (0.494--1.022)    0.066   
  rs2316709          AA                      Ref.    
  AG                 0.680 (0.408--1.135)    0.140   
  GG                 0.310 (0.089--1.080)    0.066   
  A                  Ref.                            
  G                  0.714 (0.495--1.029)    0.071   
  rs7616177          GG                      Ref.    
  GA                 0.722 (0.435--1.200)    0.209   
  AA                 0.395 (0.125--1.253)    0.115   
  G                  Ref.                            
  A                  0.744 (0.515--1.074)    0.114   

OR -- odds ratio; 95%CI -- 95% confidence intervals; Ref -- reference. In the multivariate model, the following variables were added as independent variables: age, sex, history of hypertension, duration of diabetes and glycosylated hemoglobin.

###### 

Haplotype analyses of the block 1 in the DN and NDN.

          Haplotype frequencies   P value   
  ------- ----------------------- --------- --------
  CAGGG   0.667                   0.580     0.0319
  AGAAA   0.281                   0.342     0.1172
  CAGAG   0.022                   0.026     0.7428
  CAGGA   0.015                   0.006     0.3257

###### 

Associations between *PTX3* SNPs and the risk of type 2 diabetes.

              Allele        NC (n=152)    DM (n=290)    p                      OR (95%CI)   P
  ----------- ------------- ------------- ------------- ---------------------- ------------ ---
  rs2316709   A             203 (66.8%)   386 (66.6%)   0.946                  Ref.         
  G           101 (33.2%)   194 (33.4%)                 0.847 (0.449--1.596)   0.607        
  rs2305619   A             111 (36.5%)   208 (35.9%)   0.848                  Ref.         
  G           193 (63.5%)   372 (64.1%)                 1.216 (0.656--2.254)   0.535        
  rs2120243   C             206 (67.8%)   390 (67.2%)   0.875                  Ref.         
  A           98 (32.2%)    190 (32.8%)                 0.817 (0.429--1.556)   0.539        
  rs7616177   G             204 (67.1%)   391 (67.4%)   0.926                  Ref.         
  A           100 (32.9%)   189 (32.6)                  0.837 (0.445--1.572)   0.580        
  rs2316706   G             203 (66.8%)   381 (65.7%)   0.746                  Ref.         
  T           101 (33.2%)   199 (34.3%)                 0.919 (0.494--1.708)   0.789        
  rs7634847   G             241 (79.3%)   465 (80.2%)   0.752                  Ref.         
  A           63 (20.7%)    115 (19.8%)                 0.946 (0.670--1.335)   0.752        
  rs1456099   T             153 (50.3%)   309 (53.3%)   0.405                  Ref.         
  A           151 (49.7%)   271 (46.7%)                 1.002 (0.553--1.816)   0.994        
  rs1840680   G             200 (65.8%)   377 (65.0%)   0.815                  Ref.         
  A           104 (34.2%)   203 (35.0%)                 0.827 (0.441--1.549)   0.552        

NC -- normal control; DM -- type 2 diabetes; OR -- odds ratio; 95%CI -- 95% confidence intervals; Ref -- reference. In the multivariate model, the following variables were added as independent variables: age, sex, history of hypertension, and glycosylated hemoglobin.
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